[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Arai H, Rino Y, Nishii T, Yukawa N, Wada N, Oshiro H, Ishida T, Nakaigawa N, Masuda M: Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma. Case Rep Med; 2010;2010:327591
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma.
  • Extraskeletal osteosarcoma is an uncommon high-grade malignant soft tissue sarcoma.
  • The histopathological diagnosis was well-differentiated retroperitoneal extraskeletal osteosarcoma.
  • She was followed up by CT every 6 months without adjuvant radiotherapy and chemotherapy for 31 months until anaplastic high-grade spindle cell sarcoma recurred in the retroperitoneum.
  • Our case is the seventh reported description of well-differentiated extraskeletal sarcoma, and the first to arise in the retroperitoneum and recur as an entirely dedifferentiated spindle cell sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1991 Feb;64(758):171-2 [1900726.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):906-9 [1929787.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Skeletal Radiol. 1989;18(6):471-4 [2814558.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):439-43 [15892008.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):77-8 [11271796.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] Ann Surg. 1953 Nov;138(5):795-800 [13092816.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1331-3 [7658488.001]
  • (PMID = 20224645.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2833305
  •  go-up   go-down


2. Alkatan HM, Maktabi A: Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma. Saudi J Ophthalmol; 2010 Jan;24(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology showed a moderately differentiated tumor with vitreous seeding and he received chemotherapy in addition to radiotherapy to his right eye.
  • He presented 20 years later with a right orbital tumor, frozen globe and proptosis.
  • The excisional biopsy of his orbital mass revealed a spindle cell sarcoma with features of malignant fibrous histiocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23960869.001).
  • [ISSN] 1319-4534
  • [Journal-full-title] Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
  • [ISO-abbreviation] Saudi J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3729799
  • [Keywords] NOTNLM ; Orbit / Retinoblastoma / Second tumors
  •  go-up   go-down


3. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S: Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer; 2007 May 1;109(9):1863-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
  • BACKGROUND: Single-agent gemcitabine and vinorelbine have activity in treatment of patients with soft-tissue sarcomas.
  • This study evaluated the efficacy and tolerability of gemcitabine plus vinorelbine in advanced soft-tissue sarcoma.
  • Eligible patients had unresectable or metastatic soft-tissue sarcomas, Eastern Cooperative Group performance status of 0-2, adequate organ function, and <or=1 prior regimen.
  • No treatment-related deaths occurred.
  • There has been 1 CR lasting >1 year in a patient with high-grade pleomorphic spindle-cell sarcoma.
  • CONCLUSIONS: Gemcitabine given by a fixed-dose rate of infusion combined with vinorelbine was associated with clinically meaningful rates of disease control in patients with advanced soft-tissue sarcoma.
  • This study contributed to data that have supported the administration of fixed-dose rate gemcitabine-based drug regimens in soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Female. History, 16th Century. History, 17th Century. Humans. Male. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society
  • (PMID = 17385194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


Advertisement
4. Futagami M, Yokoyama Y, Shigeto T, Mizunuma H: A case of recurrent yolk sac tumor as spindle cell sarcoma of the abdominal wall. Eur J Gynaecol Oncol; 2010;31(6):690-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurrent yolk sac tumor as spindle cell sarcoma of the abdominal wall.
  • Few studies report on tissue morphology in recurrence of yolk sac tumor.
  • The case of the recurrence of a yolk sac tumor as a spindle cell sarcoma of the abdominal wall is presented.
  • Right salpingo-oophorectomy, partial omentectomy, and extirpation of disseminated foci as fertility-preserving surgery was done since the intraoperative pathological diagnosis was yolk sac tumor.
  • Final pathological examination showed a germ cell tumor of which yolk sac tumor formed the major component including a small area that appeared to be immature nerve tissue.
  • However, the recurrence of a yolk sac tumor as an unclassified spindle cell sarcoma of the abdominal wall was found about two years after the initial surgery.
  • The mesenchyme-like component of the yolk sac tumor is characterized by spindle cells originating from epithelial elements, and is likely to give rise to a chemoresistant, diversely differentiated sarcoma.
  • This report suggests that the sarcoma reported in the case here also arose when spindle cells of the mesenchyme-like component underwent sarcomatous change during or after chemotherapy, subsequently relapsed as a chemoresistant tumor, and metastasized.
  • [MeSH-major] Abdominal Neoplasms / pathology. Endodermal Sinus Tumor / pathology. Neoplasm Recurrence, Local / pathology. Sarcoma / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319519.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Lajos P, Hasaniya N, Ehrman W, Razzouk A: Spindle cell sarcoma of the pericardium: a case report. J Card Surg; 2004 Mar-Apr;19(2):139-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell sarcoma of the pericardium: a case report.
  • Following magnetic resonance imaging and CT-guided biopsy of the mediastinal mass, spindle cell sarcoma of the pericardium was diagnosed.
  • The patient then underwent neoadjuvant chemotherapy with three cycles of ifosfamide, doxorubicin, and mesran.
  • Spindle cell sarcoma of the pericardium is a very rare tumor and other pericardial sarcomas may be best treated by combined neoadjuvant therapy followed by aggressive surgical resection when necessary, possibly utilizing cardiopulmonary bypass.
  • [MeSH-major] Heart Neoplasms / diagnosis. Pericardium / pathology. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Echocardiography, Transesophageal. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15016051.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, Pringle J, Uscinska BM, Weeden S, Kirkpatrick A, Glabbeke Mv, Craft AW, European Osteosarcoma Intergroup: Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer; 2005 Jan;41(2):225-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
  • There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B).
  • Thirty-seven patients, age 65 years, with spindle cell sarcoma of bone, except osteosarcoma or MFH-B, were included.
  • Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles.
  • Median time to progression was 30 months (95% Confidence Interval (CI), 8-51 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months).
  • Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months).
  • This study suggests a limited role for doxorubicin and cisplatin in metastatic high-grade spindle cell sarcoma of bone, other than osteosarcoma or MFH-B cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Rare Diseases / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Infusions, Intravenous. Lymphatic Metastasis. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome


7. Gupta T, Laskar S, Gujral S, Muckaden MA: Brain metastases in soft tissue sarcomas: case report and literature review. Sarcoma; 2005;9(3-4):147-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in soft tissue sarcomas: case report and literature review.
  • BACKGROUND AND PURPOSE: Brain metastasis is a relatively uncommon event in the natural history of soft tissue sarcomas.
  • The increasing use of chemotherapy may have caused a reduction in local relapses as well as distant failures leading to an improvement in survival, thereby allowing metachronous seeding of the brain, a sanctuary site.
  • PATIENTS AND METHODS: A review of the departmental sarcoma database following the presentation of this index case in the clinic.
  • RESULTS AND DISCUSSION: An adolescent male who had previously been treated with surgery and radiotherapy for a spindle cell sarcoma of the left thigh developed a space-occupying lesion in the brain within 6 months of treatment of the primary tumor.
  • On radiation he was detected to have pulmonary metastases too, for which he was offered palliative chemotherapy.
  • A review of the departmental sarcoma database, restricted to soft tissue sarcomas purely, maintained prospectively from 2000 till date, could not identify any other such case.
  • CONCLUSION: Brain metastases from soft tissue sarcomas are rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521423.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395633
  •  go-up   go-down


8. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM: Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br; 2000 Jan;82(1):55-61
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in the treatment of dedifferentiated chondrosarcoma.
  • Dedifferentiated chondrosarcoma is a rare, highly malignant variant of chondrosarcoma in which a high-grade spindle-cell sarcoma coexists with a lower-grade chondroid tumour.
  • We have reviewed our experience with this neoplasm in 22 patients, all of whom were treated using modern oncological principles of planned resection and chemotherapy.
  • Those patients who received chemotherapy, and in whom wide margins of excision were achieved at operation, did best.
  • It is essential to have an accurate preoperative diagnosis in order to plan treatment which may offer a better prospect of cure.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma / therapy

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10697315.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


9. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol; 2001 Mar 01;19(5):1238-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
  • PURPOSE: Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results.
  • PATIENTS AND METHODS: Patients between 18 and 65 years of age with grade 3 to 4 spindle-cell sarcomas (primary diameter > or = 5 cm or any size recurrent tumor) in extremities or girdles were eligible.
  • One hundred four patients were randomized, 51 to the control group and 53 to the treatment group (five cycles of 4'-epidoxorubicin 60 mg/m(2) days 1 and 2 and ifosfamide 1.8 g/m(2) days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor).
  • RESULTS: After a median follow-up of 59 months, 60 patients had relapsed and 48 died (28 and 20 in the treatment arm and 32 and 28 in the control arm, respectively).
  • The median disease-free survival (DFS) was 48 months in the treatment group and 16 months in the control group (P =.04); and the median overall survival (OS) was 75 months for treated and 46 months for untreated patients (P =.03).
  • For OS, the absolute benefit deriving from chemotherapy was 13% at 2 years and increased to 19% at 4 years (P =.04).
  • CONCLUSION: Intensified adjuvant chemotherapy had a positive impact on the DFS and OS of patients with high-risk extremity soft tissue sarcomas at a median follow-up of 59 months.
  • Therefore, our data favor an intensified treatment in similar cases.
  • Although cure is still difficult to achieve, a significant delay in death is worthwhile, also considering the short duration of treatment and the absence of toxic deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2001 Mar 1;19(5):1235-7 [11230463.001]
  • (PMID = 11230464.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Modi A, Lipnevicius A, Moorjani N, Haw M: Prolonged survival with left atrial spindle cell sarcoma. Interact Cardiovasc Thorac Surg; 2009 Jun;8(6):703-4
MedlinePlus Health Information. consumer health - Heart Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival with left atrial spindle cell sarcoma.
  • Primary spindle cell sarcoma of the left atrium is a rare tumour.
  • Optimal treatment is to obtain complete surgical clearance of the tumour.
  • The prognosis of patients with a primary cardiac sarcoma is very poor because of their resistance to treatment with chemotherapy and radiotherapy.
  • Metastases and local recurrences are common despite optimal multimodality treatment.
  • This report describes a 48-year-old gentleman who underwent multiple surgeries to achieve an 11-year survival since the diagnosis.
  • [MeSH-minor] Heart Atria / pathology. Heart Atria / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Reoperation. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304772.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Bilici A, Uygun K, Altun E, Karci E, Gurbuz Y, Semih Dogan A: Primary peritoneal spindle cell sarcoma presented with massive ascites: a case report. J BUON; 2009 Oct-Dec;14(4):721-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal spindle cell sarcoma presented with massive ascites: a case report.
  • Soft tissue sarcomas (STSs) are a heterogeneous group of rare neoplasms originating from the embryonic mesoderm and mesenchymal cells.
  • Primary peritoneal sarcomas have been reported as leiomyosarcoma, liposarcoma and carcinosarcoma.
  • However, primary peritoneal spindle cell sarcoma has never been reported in the literature.
  • Herein, we report on a 38-year-old woman with massive ascites diagnosed as primary peritoneal spindle cell sarcoma.
  • Following doxorubicin and ifosfamide chemotherapy, her symptoms improved and ascites regressed.
  • Other primary peritoneal sarcomas rarely cause massive ascites.
  • We suggest that in patients presenting with massive exudative ascites associated with malignancy, primary peritoneal sarcomas should be also considered in the differential diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / etiology. Peritoneal Neoplasms / complications. Sarcoma / complications. Soft Tissue Neoplasms / complications
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148470.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG: Sarcomas with spindle cell morphology. Semin Oncol; 2009 Aug;36(4):324-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas with spindle cell morphology.
  • In the days before the term "high-grade undifferentiated pleomorphic sarcoma" came into use, one of the most common sarcoma diagnoses was "malignant fibrous histiocytoma," and before that, in an era before immunohistochemistry, "fibrosarcoma" was used to describe most sarcomas.
  • "Spindle cell" is a descriptive phrase that denotes the cellular shape of many of the sarcomas encountered in the adult population.
  • As a result, they are usually treated differently from small round cell sarcomas, and have different biological characteristics than those tumors and sarcomas with epithelioid morphology.
  • As a very broad generalization, sarcomas with a spindle cell microscopic morphology occur in adults and are treated primarily with surgery and often adjuvant or neoadjuvant radiation as primary therapy.
  • In comparison to small round cell sarcomas such as Ewing sarcoma, the use of adjuvant chemotherapy remains controversial, and the sensitivity of these tumors to chemotherapy in the metastatic setting is highly variable.
  • In this article, we describe some of the clinical and biological characteristics of this group of sarcomas.
  • [MeSH-major] Sarcoma / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fibrosarcoma / genetics. Fibrosarcoma / pathology. Gene Fusion. Heat-Shock Response. Humans. Hyperthermia, Induced. Protein Kinase Inhibitors / therapeutic use. Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664493.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 62
  •  go-up   go-down


13. Berretta M, Rupolo M, Buonadonna A, Canzonieri V, Brollo A, Morra A, Berretta S, Bearz A, Tirelli U, Frustaci S: Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature. J Chemother; 2006 Apr;18(2):221-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature.
  • Angiosarcomas are rare soft tissue malignancies.
  • Typically they originate from the skin of the scalp or face, whereas visceral sarcomas are very rare.
  • After surgical removal, a rapid peritoneal, visceral and cutaneous diffusion developed.
  • Palliative chemotherapy, based on anthracycline and ifosfamide, which are normally used to treat all other high-grade spindle cell sarcomas, was totally inactive.
  • On the basis of these results and of the biological characteristics of these rare neoplasms it is mandatory to develop other therapeutic approaches.
  • Antiangiogenetic agents are of interest for this disease due to the peculiar origin of the cells of these sarcomas.
  • [MeSH-major] Hemangiosarcoma / drug therapy. Hemangiosarcoma / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery
  • [MeSH-minor] Aged. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Ifosfamide / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Nephrectomy. Palliative Care. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736893.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Ottaiano A, Pisano C, De Chiara A, Barletta E, Ascierto AP, Botti G, Napolitano M, Apice G, Iaffaioli RV: Expression of CD40 has no predictive value in soft tissue sarcomas. Anticancer Res; 2003 Mar-Apr;23(2B):1597-604
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 has no predictive value in soft tissue sarcomas.
  • BACKGROUND: CD40, a member of the tumor necrosis factor receptor superfamily, is capable of mediating the induction of apoptosis in tumors including sarcomas.
  • The expression of proapoptotic receptor contribute to the induction of apoptosis by chemotherapeutic drugs.
  • The present study was undertaken to determine if there is a correlation between the expression of CD40 in spindle-cell sarcomas and the response to epirubicin and ifosfamide chemotherapy.
  • PATIENTS AND METHODS: Immunohistochemical analysis of CD40 expression was performed on 59 paraffin-embedded archival tissues.
  • Correlations with response to chemotherapy and baseline patients' characteristics were investigated using Chi-square tests.
  • No significant association was found between CD40 expression, response to chemotherapy and other clinical and pathological characteristics.
  • CONCLUSION: CD40 expression in spindle-cell soft tissue sarcomas is not associated with response to ifosfamide plus epirubicin chemotherapy.
  • [MeSH-major] Antigens, CD40 / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Sarcoma / chemistry. Soft Tissue Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Epirubicin / administration & dosage. Epirubicin / pharmacology. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / pharmacology. Male. Mesna / administration & dosage. Middle Aged. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820428.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, Neoplasm; 3Z8479ZZ5X / Epirubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain.
  • : e21526 Background: Primary sarcomas of the breast (PBS) are a heterogeneous group of tumors from stromal breast, infrequent (0.1% of BC).
  • Diagnosis and treatment is unclear.
  • Heterogeneous chemotherapy/radiotherapy schedules was evaluated .
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Adjuvant therapy was radiation 57.14% pts; and chemotherapy (doxorubicin 4/liposomal doxorubicin 2 pts) in recurrence.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, Yano T: In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res; 2001 Nov-Dec;21(6A):4147-51
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity of human soft tissue sarcoma.
  • Chemotherapy is essential in the treatment of small round cell sarcomas.
  • However, as yet there is no progress concerning the efficacy of chemotherapy in the treatment of other types of soft tissue tumors (STS).
  • The Histoculture Drug Response Assay (HDRA) is an in vitro chemosensitivity test that has a high correlation with clinical response, the usefulness of which has been reported in various kinds of solid tumors.
  • Drug sensitivity testing by HDRA showed that two drugs, ADM and THP, had a significantly higher inhibitory rate than CDDP, IFOS, or VP-16 in the thirty-three soft tissue sarcomas tested.
  • Depending on the morphological type, spindle cell sarcomas were sensitive to THP, which showed significantly higher inhibition rates than CDDP, IFOS, or VP-16.
  • Small round cell sarcomas were relatively sensitive to all of the drugs tested.
  • However the drug sensitivity of pleomorphic cell sarcoma was low except for ADM and THP, while its sensitivity to THP was higher than about 70%.
  • However, there are numerous other soft tissue sarcomas that do not belong to these categories; drug sensitivity testing in each of them and the devising of individualized treatment strategies seems necessary to improve the therapeutic outcome.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Doxorubicin / analogs & derivatives. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911309.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


17. Chowdhry M, Hughes C, Grimer RJ, Sumathi V, Wilson S, Jeys L: Bone sarcomas arising in patients with neurofibromatosis type 1. J Bone Joint Surg Br; 2009 Sep;91(9):1223-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone sarcomas arising in patients with neurofibromatosis type 1.
  • We identified eight patients of 2900 with a primary malignant bone tumour who had coexisting neurofibromatosis type 1.
  • Two patients subsequently developed a second bone sarcoma, one of which was radiation induced.
  • Four of the primary tumours were osteosarcomas, four were spindle-cell sarcomas and one a Ewing's sarcoma.
  • All the patients were treated with chemotherapy and surgery: six of the eight appear to be cured.
  • This study suggests a possible relationship between neurofibromatosis type 1 and the development of a bone sarcoma, the increased risk being estimated at eight times that of the normal population.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neurofibromatosis 1 / pathology. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Dose-Response Relationship, Radiation. Female. Humans. Incidence. Male. Middle Aged. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / therapy. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721051.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • Similarities in morphology and biological behavior compared to patients with "triple-negative" (hormone receptor and Her2) monophasic sarcomatoid carcinomas and pure spindle cell sarcomas are discussed.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Humans. Middle Aged


19. Hasegawa T, Yamamoto S, Nojima T, Hirose T, Nikaido T, Yamashiro K, Matsuno Y: Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol; 2002 Jan;33(1):111-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas.
  • Soft-tissue sarcomas in adults show great variations in histologic type and grade.
  • A valid and reproducible prognostication system is needed to select patients with soft-tissue sarcomas who could benefit from adjuvant chemotherapy.
  • This study was conducted to assess the validity and reproducibility of diagnosis of the histologic type, MIB-1 grade, and mitosis grade, as well as of the 3 components of these grading systems.
  • MIB-1 grade is a recently proposed grading system for predicting the prognosis of patients with adult soft-tissue sarcomas on the basis of 3 criteria (tumor differentiation, necrosis, and MIB-1 score) and replaces the mitotic count in the French system with MIB-1 immunohistochemical staining.
  • Four surgical pathologists from 4 institutions who had experience in diagnostic soft-tissue tumor pathology reviewed 130 cases of soft-tissue sarcoma and independently determined histologic type and grade.
  • The validity of histologic diagnosis was measured by sensitivity and specificity, and that of grading was measured by kappa statistics and percentage agreement with the diagnosis of the expert panel at the National Cancer Center, which was defined as a gold standard.
  • The validity of the diagnosis of histologic type was high for synovial sarcoma, small round-cell sarcoma, and liposarcoma (sensitivity 89% to 100%; specificity, 98% to 100%) but low for malignant fibrous histiocytoma (MFH) and spindle-cell sarcoma (73% to 75%; 93% to 95%).
  • Interobserver reproducibility of histologic diagnosis was high for small round-cell sarcoma, synovial sarcoma, and liposarcoma (kappa = 0.92, 0.90, 0.87; percentage agreement = 99%, 97%, 96%, respectively); for grading, reproducibility was highest for tumor differentiation (0.78; 87%) and second highest for MIB-1 grade (0.68; 79%).
  • We conclude that diagnosis of the type of soft-tissue sarcoma for synovial sarcoma, small round-cell sarcoma, and liposarcoma and the MIB-1 grading system based on tumor differentiation are highly valid and reproducible among Japanese pathologists who are familiar with the grading system, whereas re-evaluation of histologic criteria is essential for other histologic types such as MFH and spindle-cell sarcoma.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by W.B. Saunders Company
  • (PMID = 11823981.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Ki-67 Antigen; 0 / Nuclear Proteins
  •  go-up   go-down


20. Wei CF, Hwang SH, Ho CM, Shih BY, Chien TY: Malignant mixed müllerian tumors of the ovary. Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr;63(4):344-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 was a 59-year-old female with stage IIIC MMMT of the ovary, with a tumor having carcinomatous and sarcomatous elements.
  • The carcinomatous component was composed of a high-grade epithelial malignancy including serous, endometrioid, clear cell and undifferentiated carcinoma elements.
  • The carcinomatous component was composed of grade II-III clear cell carcinoma and the sarcomatous component was composed of high-grade non-specific spindle cell sarcoma, which was positive for vimentin, but negative for cytokeratin, desmin and S-100 protein on immunostaining.
  • These two patients both underwent hysterectomy, bilateral salpingo-oophorectomy and omentectomy and both received platinum-based chemotherapy after debulking surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820916.001).
  • [ISSN] 0578-1337
  • [Journal-full-title] Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi (Taipei)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] CHINA
  •  go-up   go-down


21. Kim JY, Cho YM, Ro JY: Prostatic stromal sarcoma with rhabdoid features. Ann Diagn Pathol; 2010 Dec;14(6):453-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic stromal sarcoma with rhabdoid features.
  • Rhabdoid tumors have been reported in many different anatomic sites as an aggressive tumor and usually present with a rhabdoid tumor component (a composite tumor) rather than a pure rhabdoid tumor.
  • Rhabdoid features in prostatic stromal sarcomas (PSSs) have never been described in the literature.
  • A 31-year-old man presented with a 4-month history of voiding difficulty and anal pain.
  • Computed tomography of the abdomen revealed an ovoid mass in the prostate invading rectum and urinary bladder.
  • A needle biopsy was diagnosed as an unclassified spindle cell sarcoma, and 2 cycles of adriamycin-based neoadjuvant chemotherapy were given, followed by radical prostatectomy.
  • The prostatectomy specimen revealed a high-grade sarcoma with fascicles of highly cellular spindle cells and numerous mitoses with hemorrhage and necrosis.
  • Both spindle and rhabdoid tumor cells were positive for vimentin, CD34, and progesterone receptor and negative for desmin and cytokeratin immunostainings.
  • The tumor showed an aggressive clinical behavior with a short-term survival (7 months after diagnosis).
  • [MeSH-major] Prostatic Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074696.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


22. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the breast.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • Majority of the series include both stromal and cystosarcoma phyllodes, only a few hundred cases of sarcomas other then cystosarcoma are reported.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 19 patients with primary sarcoma of the breast treated between 1982 and 2002.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • CONCLUSIONS: Primary sarcomas of the breast are aggressive tumors.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Shi X, Wu S, Zhao J: [Limb salvage with osteoarticular allografts after resection of proximal tibia bone]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):966-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1998 to 2003, 15 patients (7 males, 8 females; aged 14-56 yr. average 33) with bone tumor of the proximal tibia underwent osteoarticular allografts. among whom 7 had progressive giant cell tumor without any previous chemotherapy; 8 had malignant tumor with previous chemotherapy, including 6 patients with osteosarcoma, 1 with spindle cell sarcoma, and 1 with malignant fibrous histiocytoma.
  • RESULTS: The follow-up for an average of 21 months (range, 3-58 months) revealed that among the 8 patients with malignant tumor of the proximal tibia undergoing chemotherapy, 5 had union of the bone, 3 had no union of the bone; among the 3 patients, 2 had a complication of infection and 1 had a local recurrence.
  • According to the Mankin score, 2 patients had a perfect result, 2 good, 1 fair, and 3 poor, with a 50% effectiveness rate.
  • Among the 7 patients with progressive giant cell tumor at the upper part of the tibia, none had infection or local recurrence, but 2 had nonunion of the bone and 2 had joint instability, aided by the knee-aiding system.
  • According to the Mankin score, 3 patients had a perfect result, 2 good, and 2 fair, with a 71% effectiveness rate.
  • [MeSH-minor] Adolescent. Adult. Bone Transplantation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140064.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Malerba M, Garofalo A: [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)]. Tumori; 2003 Jul-Aug;89(4 Suppl):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of nerve-sheath sarcoma with rhabdomyoblastic differentiation (malignant triton tumor)].
  • [Transliterated title] Un raro caso di sarcoma delle guaine nervose a differenziazione rabdomioblastica (malignant Triton tumor).
  • Malignant peripheral nerve sheath tumors (MPNST) are spindle-cell sarcomas that appear in a setting of neurofibroma or schwannoma or are associated with peripheral nerves or demonstrate nerve sheath differentiation.
  • Malignant triton tumor (MTT) is a subtype of MPNST that also contain tissue with skeletal muscle differentiation (embryonal, plemorphic and botryoid rhabdomyosarcoma).
  • Seventeen months before, when the patient underwent surgery at the same Department for both a left-sided paravertebral inferior mediastinal neurofibroma and a right-sided axillary neurofibroma, diagnosis of von Recklinghausen disease (NF1) was made, according to the criteria established by the NIH Consensus Development.
  • The popliteal mass was resected too and resulted to be a neurofibroma just like the tumors resected 17 months before when diagnosis of von Recklinghausen disease was made.
  • Sarcoma arising in anatomic site other than extremity and superficial trunk are often more difficult to control because of anatomic constraints, delayed disease presentation, proximity to neurovascular and osseous structures and toxicity for normal adjacent tissues that limits the use of adequate radiation doses.
  • Reported local recurrence rates for retroperitoneal sarcomas range from 40% to 80% and, in marked contrast to extremity STS, most of patients can and do die from local recurrence in the absence of metastasis.
  • In contrast to the benefit most patients with high grade soft tissue sarcomas of the extremities receive from adjuvant radiation and chemotherapy, these modalities have been of little value for retroperitoneal tumors.
  • Current chemotherapy for retroperitoneal sarcomas is ineffective.
  • Local adjuvant therapy such as intraperitoneal chemotherapy or experimental immunotherapy seems to be attractive in theory, but needs further investigations through prospective randomized multicentric trials.
  • In conclusion, to date aggressive surgical management remains the most effective modality for selected primary and recurrent retroperitoneal soft tissue sarcomas including MPNSTs and the subtype MTT.
  • Patients with incomplete resection and other risk factors such as younger age and high grade tumors may be suitable candidates for investigational adjuvant therapy.
  • [MeSH-minor] Adult. Axilla. Cell Differentiation. Humans. Knee. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Muscles / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12903608.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Chen HJ, Xu M, Zhang L, Zhang YK, Wang GM: [Prostate sarcoma: a report of 14 cases]. Zhonghua Nan Ke Xue; 2005 Sep;11(9):683-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate sarcoma: a report of 14 cases].
  • OBJECTIVE: To discuss the diagnosis and effective treatment of prostate sarcoma.
  • METHODS: We analysed the clinical materials of fourteen patients with prostate sarcoma treated in our hospital from Jan.
  • RESULTS: Prostate sarcoma accounted for 3.21% of all the prostatic malignant tumors treated in our hospital during that period.
  • Pathological test revealed: 7 cases leiomyosarcoma, 1 case rhabdomyosarcoma, 4 cases fibrosarcoma, 2 cases spindle cell sarcoma.
  • Different kinds of prostate sarcoma each his its own immuno-histochemical staining features.
  • All the patients received surgery, chemotherapy and/or radiotherapy.
  • One case failed to be followed up, 11 died 2 approximately 12 months after diagnosis.
  • CONCLUSION: Dysuria is always the first symptom of prostate sarcoma.
  • DRE test may suggest prostate sarcoma but needle biopsy contributes to a definite diagnosis.
  • The prognosis of prostate sarcoma is very poor and the main treatment is surgery followed by chemotherapy and/or radiotherapy.
  • [MeSH-major] Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy


26. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 1981 May 15;47(10):2422-9 [7272896.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Ter. 1998 Mar-Apr;149(2):121-5 [9780476.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Berrebi O, Steiner C, Keller A, Rougemont AL, Ratib O: F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med; 2008 Jul;33(7):469-71
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones.
  • Fibrous dysplasia (FD) is a benign dysplastic pathology of bone-forming mesenchymal cells, resulting in replacement of trabecular bone by abnormal fibrous and immature osseous tissue.
  • We report the case of a 59-year-old woman with monostotic FD of the left ischium, known for over 30 years, who developed sarcomatous transformation in a low-grade spindle-cell sarcoma.
  • The value of F-18 fluorodeoxyglucose positron emission tomography in the early diagnosis of malignant transformation, the evaluation of distant metastasis, as well as monitoring the efficacy of chemotherapy are discussed.
  • [MeSH-major] Fibrous Dysplasia of Bone / diagnosis. Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Pelvis / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Bone and Bones / radionuclide imaging. Cell Proliferation. Cell Transformation, Neoplastic. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography / methods. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580231.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 174800
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Pérez Serna AG, Moreno Hoyos LF, Ramírrez Valdivia S: [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture]. Acta Ortop Mex; 2009 Nov-Dec;23(6):351-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture].
  • [Transliterated title] Cirugía de salvamento como alternativa en el tratamiento de osteosarcoma de rodilla ante la presencia de fractura en terreno patológico.
  • INTRODUCTION: classical osteosarcoma is defined as a very malignant spindle cell sarcoma, characterized by the production of osteoid matrix, it is the most common primary malignant bone tumor.
  • Conservative surgery is inappropriate; however, preoperative chemotherapy and a good choice of conservative treatment are an alternative.
  • MATERIAL AND METHODS: a 15-year-old male patient presented at the orthopedics service with a diagnosis of a pathological fracture in the distal third of the right femur and a tumor in the lateral aspect of the knee, with pain and limitation of gait.
  • Based on X-rays, a bone scan and a biopsy, the diagnosis of a fibroblastic osteosarcoma, an Enneking IIB lesion, was made.
  • Treatment consisted of conservative surgery with broad tumor resection involving 18 cm of the femur, resection of the vastus medialis and vastus lateralis, release of the femoral bundle, the popliteal and sciatic nerves, as well as placement of a modular stryker tumor prosthesis, with knee replacement.
  • We think that staging is essential to select the treatment.
  • In the case presented herein a comprehensive management is fundamental to the success of conservative treatment.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Gait. Humans. Limb Salvage. Male. Quadriceps Muscle / surgery. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377001.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


29. Yura S, Terahata S, Ohga N, Yamashita T: A case of carcinosarcoma arising in the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):820-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total excision of the left submandibular gland with radical neck dissection was performed under a diagnosis of a submandibular tumor, probably a malignant mixed tumor.
  • The pathologic diagnosis was carcinosarcoma consisting of carcinomatous and sarcomatous elements.
  • The epithelial component was composed of squamous cell carcinoma, undifferentiated carcinoma, and adenocarcinoma.
  • The nonepithelial component was composed of chondrosarcoma, osteosarcoma, spindle cell sarcoma, rhabdomyosarcoma, and liposarcoma.
  • In view of the expected aggressive nature of the tumor, the patient was treated with postoperative radiotherapy of 60 Gy total, in 30 daily fractions of 2 Gy, and chemotherapy.
  • He currently remains well and free of disease 24 months after treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531942.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Rana SS, Balamurali S, Dronamraju VA, Batra YK, Vasishta RK, Kumar Y: Unusual malignant tracheal tumour presenting with acute airway obstruction. Indian J Chest Dis Allied Sci; 2007 Jan-Mar;49(1):49-51
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology of the mass revealed it to be a spindle cell sarcoma.
  • Subsequently, local irradiation and systemic chemotherapy was given.
  • [MeSH-major] Airway Obstruction / etiology. Sarcoma / pathology. Tracheal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256568.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down






Advertisement